

Solriamfetol 75mg and 150mg film-coated tablets (Sunosi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2439	To improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). SMC restriction: for use in patients who have failed modafinil or have a contraindication or intolerance to modafinil.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/10/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/solriamfetol-sunosi-narcolepsy-full-smc2439/>

Other Decision Specified

Date of ADTC 20/07/2022

Delafloxacin 450mg tablets and 300mg powder for concentrate for solution for infusion (Quofenix®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2453	<p>Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection.</p> <p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p> <p>SMC restriction: Patients with suspected or confirmed polymicrobial infection following treatment failure or when standard antibacterial therapies are not suitable.</p> <p>Delafloxacin should be used on the advice of local microbiologists or specialists in infectious disease.</p>	<p>Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by</p>	31/10/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/delafloxacin-quofenix-full-smc2453/>

Other Decision Specified

Date of ADTC 20/07/2022

Pegcetacoplan 1,080mg solution for infusion (Aspaveli®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2451	In the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months. SMC restriction: under the advice of the national PNH service.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/10/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/pegcetacoplan-aspaveli-full-smc2451/>

Other Decision Specified

Date of ADTC 20/07/2022

Vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2506	Treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.	Not routinely available as not recommended for use in NHS Scotland	20/07/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/vedolizumab-entyvio-non-sub-smc2506/>

Other Decision Specified

Date of ADTC 20/07/2022

Enfortumab vedotin 20mg and 30mg powder for concentrate for solution for infusion (Padcev®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2505	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.	Not routinely available as not recommended for use in NHS Scotland	20/07/2022

Web Links

<https://www.scottishmedicines.org.uk/medicines-advice/enfortumab-vedotin-padcev-non-sub-smc2505/>

Other Decision Specified

Date of ADTC 20/07/2022

Crizanlizumab 10mg/mL concentrate for solution for infusion (Adakveo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2438	For the prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxycarbamide or as monotherapy in patients for whom hydroxycarbamide is inappropriate or inadequate.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/10/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/crizanlizumab-adakveo-full-smc2438/>

Other Decision Specified

Date of ADTC 20/07/2022

Odevixibat 200, 400, 600 and 1,200 microgram hard capsules (Bylvay®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2411	For the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.	Available in line with national guidance	20/07/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/odevixibat-bylvay-ultra-orphan-initial-assessment-smc2411/>

Other Decision Specified

Date of ADTC 20/07/2022